NextCell Pharma AB (NXTCL) AI Stock Analysis

• Market Cap: €133.00M
• Dividend Yield: N/A
• Average Volume (3M): 312.11K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.30
• Revenue Growth: -15.28%
• EPS Growth: 36.01%
• Country: SE
• Employees: 24
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 111,392,960
• 10 Day Avg. Volume: 139,721
• 30 Day Avg. Volume: 312,108
• PEG Ratio: 1.28
• Price to Book (P/B): 1.37
• Price to Sales (P/S): 8.70
• P/FCF Ratio: -2.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

NextCell Pharma AB's stock score reflects significant challenges in profitability and liquidity, despite revenue growth and a strong balance sheet. Technical indicators suggest weak market momentum with an oversold condition, while valuation metrics are unattractive due to negative earnings. The company needs to address operational inefficiencies to improve its financial standing.

NextCell Pharma AB Business Overview & Revenue Model

Company Description

NextCell Pharma AB (NXTCL) is a Swedish biopharmaceutical company focused on the development and commercialization of advanced therapies for immune-related diseases. The company specializes in stem cell-based treatments, with its flagship product, ProTrans, developed for the treatment of autoimmune conditions such as Type 1 Diabetes. NextCell Pharma operates within the biotechnology and healthcare sectors, aiming to leverage cutting-edge research to provide innovative therapeutic solutions.

How the Company Makes Money

NextCell Pharma AB generates revenue primarily through the development and commercialization of its proprietary stem cell-based treatments. The company earns money by advancing its products through clinical trials and eventually licensing them to larger pharmaceutical companies for distribution and sale. Partnerships and collaborations with research institutions and healthcare organizations play a significant role in the company's business model, providing financial support for research and development activities. Additionally, NextCell Pharma seeks to secure grants and funding from government and non-governmental entities to support its innovative research efforts.

NextCell Pharma AB Financial Statement Overview

Summary

NextCell Pharma AB is experiencing revenue growth within the biotechnology sector, but it faces significant profitability challenges with negative margins. The balance sheet remains strong with no debt, but liquidity pressures persist, as evidenced by negative cash flows. The company must focus on improving operational efficiency and managing costs to sustain long-term growth.

Income Statement

NextCell Pharma AB displays consistent revenue growth over the years, with a notable increase from 2023 to 2024. However, the company struggles with negative gross profit and net profit margins, indicating high costs relative to revenues. The EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company has a robust equity position with a strong equity ratio and zero debt, reducing financial risk. However, the declining stockholders' equity over the past years suggests pressure on maintaining asset levels. Despite this, the absence of debt provides significant financial stability.

Cash Flow

Operating cash flow remains negative, and free cash flow is under pressure, reflecting challenges in generating cash from operations. However, recent improvements in free cash flow growth are noted. The company relies on financing activities to support cash flow needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.98M	10.66M	10.11M	5.59M	3.91M	3.56M
Gross Profit	-12.49M	-4.56M	-884.83K	-22.26M	-14.53M	-10.37M
EBITDA	-37.21M	-40.99M	-39.36M	-34.10M	-24.21M	-17.28M
Net Income	-39.76M	-41.96M	-39.81M	-34.08M	-24.56M	-17.69M
Balance Sheet
Total Assets	52.21M	81.29M	88.83M	124.66M	155.63M	29.77M
Cash, Cash Equivalents and Short-Term Investments	16.71M	46.79M	50.03M	97.12M	139.17M	21.96M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	11.12M	13.69M	13.10M	9.12M	5.53M	3.56M
Stockholders Equity	41.09M	67.60M	75.73M	115.54M	150.09M	26.22M
Cash Flow
Free Cash Flow	-38.49M	-37.86M	-47.92M	-40.90M	-26.30M	-19.75M
Operating Cash Flow	-36.05M	-37.78M	-43.83M	-33.31M	-25.58M	-18.96M
Investing Cash Flow	-2.50M	-83.51K	-4.10M	-9.37M	-5.84M	-590.01K
Financing Cash Flow	34.46M	34.63M	835.66K	608.17K	148.63M	21.38M

NextCell Pharma AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.15
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NXTCL, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 1.19, above the 50-day MA of 1.10, and below the 200-day MA of 1.94, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.68 is Neutral, neither overbought nor oversold. The STOCH value of 57.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NXTCL.

NextCell Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	kr6.06B	7.76	-27.68%	2.23%	51.29%	15.89%
ELIC	47 Neutral	€284.42M	―	-57.25%	―	―	45.99%
NXTCL	47 Neutral	€133.00M	―	-89.24%	―	-15.28%	36.01%
ACE	43 Neutral	€538.94M	―	-138.29%	―	―	33.20%
XINT	43 Neutral	kr266.32M	―		―	975.86%	48.78%
SPAGO	38 Underperform	kr92.27M	―	-90.43%	―	29.54%	63.07%